Successful treatment of adult‐onset nesidioblastosis by continuous subcutaneous octreotide infusion in a patient on hemodialysis

Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side‐effects and stabilize plasma glucose levels. Octreotide may be useful in noninsulinoma pancreatogenous h...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 9; no. 1; pp. 278 - 281
Main Authors Kato, Rina, Nishimura, Akihiro, Matsumura, Kimio, Kikuno, Shota, Nagasawa, Kaoru, Mori, Yasumichi
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.01.2021
John Wiley and Sons Inc
Wiley
Subjects
Case Report
Case Reports
Glucose
Hemodialysis
Hypoglycemia
Insulin
Insulin-like growth factors
Laboratories
Localization
Meals
nesidioblastosis
octreotide
Pancreaticoduodenectomy
Patients
Peptides
Plasma
Surgery
Veins & arteries
nesidioblastosis
hemodialysis
octreotide
Online AccessGet full text

Cover

More Information
Summary:Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side‐effects and stabilize plasma glucose levels. Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side‐effects and stabilize plasma glucose levels.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.3514